Foreword: message from the Editor.

*Author for correspondence: r.wijayatunga@futuremedicine.com We have come to the final issue of volume 5 of Lung Cancer Management and would like to thank all the authors and reviewers, along with our editorial and production teams (both internal and external) for their contribution in making volume 5 another great one! We certainly value their hard work, dedication and cooperation throughout this year. The journal has been well supported by our knowledgeable and helpful Editorial Advisory Board, headed by our Editor-in-Chief David J Sugarbaker, Baylor College of Medicine, USA. Their time and effort, be it in an ambassadorial, advisory or authorship role, on behalf of Lung Cancer Management, are very much appreciated and valued, and we extend a big thank you to them all. As with all the past volumes of Lung Cancer Management, the standard of content published in volume 5 has been very high – having been assessed using our rigorous peer review and revisions process. We have published a wide range of article types in volume 5, from the shorter opinion and discussion-based editorial and commentary articles, case reports and original research, as well as the longer reviewer articles, covering a variety of subject areas including, neurotrophic tyrosine kinase gene fusions, oligometastatic lung cancer, advanced NSCLC, immunotherapy, symptom burden, liquid biopsy, immune checkpoint inhibitors and surgery. Many articles proved to be popular with our readers through this year and some of the most read articles so far include: ● Review: Nintedanib in advanced NSCLC: management of adverse events (by Lemmens) [1];